inositol has been researched along with Overweight in 19 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study strove to investigate the hypothesis that a low dosage of myo-inositol supplementation might decrease the likelihood of gestational diabetes in overweight, pregnant women." | 9.69 | The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial. ( Basirat, Z; Delavar, MA; Esmaeilzadeh, S; Ghadimi, R; Mashayekh-Amiri, S, 2023) |
| "To determine whether a combined myo-inositol, probiotics and micronutrient nutritional supplement impacts time-to-natural-conception and clinical pregnancy rates." | 9.69 | Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics, and micronutrient supplement: secondary outcomes of the NiPPeR randomized trial. ( Baker, PN; Barton, SJ; Chan, SY; Chang, HF; Chong, YS; Cutfield, WS; Ebreo, M; El-Heis, S; Godfrey, KM; Kenealy, T; Loy, SL; Nield, H; Ong, J; Tan, KM; Titcombe, P; Wong, JT, 2023) |
| " Inclusion criteria were randomized controlled trials (RCTs) that enrolled overweight and obese pregnant women and used myo-inositol supplementation." | 9.41 | The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis. ( Corpuz, H; Factor, PA, 2023) |
| "This study aims to evaluate the effects of myo-inositol supplementation on gestational diabetes mellitus (GDM) rates and body water distribution in overweight non-obese women." | 9.41 | Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes - a randomized and open-label, placebo-controlled clinical trial. ( Caruso, S; Cianci, A; Corrado, F; D'Anna, R; Di Benedetto, A; Giunta, L; Vitale, SG, 2021) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 9.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| "To evaluate whether myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) rate in overweight women." | 9.22 | Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. ( Corrado, F; D'Anna, R; Di Benedetto, A; Facchinetti, F; Neri, I; Petrella, E; Pintaudi, B; Santamaria, A, 2016) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 9.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| "Forty-three polycystic ovary syndrome (PCOS) overweight/obese patients were randomly treated for 6 months with: only diet (Group 1, n = 21); diet and myo-inositol (MI) 4 g + folic acid 400 µg daily (group 2, n = 10); diet in association with MI 1." | 7.91 | Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. ( Alibrandi, A; Benvenga, S; Le Donne, M; Metro, D; Papa, M, 2019) |
| " On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,." | 6.77 | Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. ( Artini, PG; Campedelli, A; Chierchia, E; Genazzani, AD; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2012) |
| "This study strove to investigate the hypothesis that a low dosage of myo-inositol supplementation might decrease the likelihood of gestational diabetes in overweight, pregnant women." | 5.69 | The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial. ( Basirat, Z; Delavar, MA; Esmaeilzadeh, S; Ghadimi, R; Mashayekh-Amiri, S, 2023) |
| "To determine whether a combined myo-inositol, probiotics and micronutrient nutritional supplement impacts time-to-natural-conception and clinical pregnancy rates." | 5.69 | Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics, and micronutrient supplement: secondary outcomes of the NiPPeR randomized trial. ( Baker, PN; Barton, SJ; Chan, SY; Chang, HF; Chong, YS; Cutfield, WS; Ebreo, M; El-Heis, S; Godfrey, KM; Kenealy, T; Loy, SL; Nield, H; Ong, J; Tan, KM; Titcombe, P; Wong, JT, 2023) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 5.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| " Inclusion criteria were randomized controlled trials (RCTs) that enrolled overweight and obese pregnant women and used myo-inositol supplementation." | 5.41 | The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis. ( Corpuz, H; Factor, PA, 2023) |
| "This study aims to evaluate the effects of myo-inositol supplementation on gestational diabetes mellitus (GDM) rates and body water distribution in overweight non-obese women." | 5.41 | Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes - a randomized and open-label, placebo-controlled clinical trial. ( Caruso, S; Cianci, A; Corrado, F; D'Anna, R; Di Benedetto, A; Giunta, L; Vitale, SG, 2021) |
| "To improve insulin sensitivity, insulin-sensitizing drugs such as metformin are commonly used in overweight and obese T1D patients." | 5.24 | A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes. ( Defeudis, G; Del Toro, R; Fioriti, E; Guglielmi, C; Kyanvash, S; Maggi, D; Manfrini, S; Maurizi, AR; Menduni, M; Pantano, AL; Pozzilli, P, 2017) |
| "To evaluate whether myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) rate in overweight women." | 5.22 | Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial. ( Corrado, F; D'Anna, R; Di Benedetto, A; Facchinetti, F; Neri, I; Petrella, E; Pintaudi, B; Santamaria, A, 2016) |
| " Since it has been demonstrated a high incidence of insulin resistance in PCOS patients, our study aimed to evaluate the efficacy of the integrative treatment with D-chiro-inositol (DCI) (500 mg die, per os, for 12 weeks) on hormonal parameters and insulin sensitivity in a group of overweight/obese PCOS patients (body mass index; BMI > 26)." | 5.19 | Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients. ( Chierchia, E; Despini, G; Genazzani, AD; Marini, G; Prati, A; Rattighieri, E; Santagni, S; Simoncini, T, 2014) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 5.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| "Forty-three polycystic ovary syndrome (PCOS) overweight/obese patients were randomly treated for 6 months with: only diet (Group 1, n = 21); diet and myo-inositol (MI) 4 g + folic acid 400 µg daily (group 2, n = 10); diet in association with MI 1." | 3.91 | Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome. ( Alibrandi, A; Benvenga, S; Le Donne, M; Metro, D; Papa, M, 2019) |
| "Myo-inositol treatment in early pregnancy is associated with a reduction in the rate of gestational diabetes mellitus and in the risk of preterm birth and macrosomia in women who are at risk for gestational diabetes mellitus." | 3.88 | Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs. ( Alibrandi, A; Corrado, F; D'Anna, R; Di Benedetto, A; Facchinetti, F; Pintaudi, B; Santamaria, A, 2018) |
| "Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular (CV) events." | 2.87 | Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism. ( Badimon, L; Cubedo, J; Hernández-Mijares, A; Lambert, C; López-Bernal, S; Padró, T; Rocha, M; Vilahur, G, 2018) |
| " On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,." | 2.77 | Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. ( Artini, PG; Campedelli, A; Chierchia, E; Genazzani, AD; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2012) |
| "Polycystic ovary syndrome is characterized by several endocrine impairments, insulin resistance and hyperinsulinemia." | 1.51 | Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. ( Genazzani, AD; Marchini, F; Napolitano, A; Petrillo, T; Prati, A; Simoncini, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 6 (31.58) | 2.80 |
| Authors | Studies |
|---|---|
| Esmaeilzadeh, S | 1 |
| Ghadimi, R | 1 |
| Mashayekh-Amiri, S | 1 |
| Delavar, MA | 1 |
| Basirat, Z | 1 |
| Chan, SY | 1 |
| Barton, SJ | 1 |
| Loy, SL | 1 |
| Chang, HF | 1 |
| Titcombe, P | 1 |
| Wong, JT | 1 |
| Ebreo, M | 1 |
| Ong, J | 1 |
| Tan, KM | 1 |
| Nield, H | 1 |
| El-Heis, S | 1 |
| Kenealy, T | 1 |
| Chong, YS | 1 |
| Baker, PN | 1 |
| Cutfield, WS | 1 |
| Godfrey, KM | 1 |
| Factor, PA | 1 |
| Corpuz, H | 1 |
| Artini, PG | 2 |
| Obino, MER | 1 |
| Micelli, E | 1 |
| Malacarne, E | 1 |
| Vacca, C | 1 |
| Papini, F | 1 |
| Cela, V | 1 |
| Vitale, SG | 1 |
| Corrado, F | 3 |
| Caruso, S | 1 |
| Di Benedetto, A | 3 |
| Giunta, L | 1 |
| Cianci, A | 1 |
| D'Anna, R | 3 |
| Hernandez Marin, I | 1 |
| Picconi, O | 1 |
| Laganà, AS | 1 |
| Costabile, L | 1 |
| Unfer, V | 1 |
| Bond, DJ | 1 |
| Silveira, LE | 1 |
| MacMillan, EL | 1 |
| Torres, IJ | 1 |
| Lang, DJ | 1 |
| Su, W | 1 |
| Honer, WG | 1 |
| Lam, RW | 1 |
| Yatham, LN | 1 |
| Lambert, C | 1 |
| Cubedo, J | 1 |
| Padró, T | 1 |
| Vilahur, G | 1 |
| López-Bernal, S | 1 |
| Rocha, M | 1 |
| Hernández-Mijares, A | 1 |
| Badimon, L | 1 |
| Santamaria, A | 2 |
| Alibrandi, A | 3 |
| Pintaudi, B | 2 |
| Facchinetti, F | 2 |
| Le Donne, M | 2 |
| Metro, D | 1 |
| Papa, M | 1 |
| Benvenga, S | 1 |
| Genazzani, AD | 4 |
| Prati, A | 3 |
| Marchini, F | 1 |
| Petrillo, T | 1 |
| Napolitano, A | 1 |
| Simoncini, T | 3 |
| Morgante, G | 1 |
| Musacchio, MC | 1 |
| Orvieto, R | 1 |
| Massaro, MG | 1 |
| De Leo, V | 1 |
| Santagni, S | 2 |
| Rattighieri, E | 2 |
| Chierchia, E | 2 |
| Despini, G | 1 |
| Marini, G | 1 |
| Simmons, D | 1 |
| Petrella, E | 1 |
| Neri, I | 1 |
| Maurizi, AR | 1 |
| Menduni, M | 1 |
| Del Toro, R | 1 |
| Kyanvash, S | 1 |
| Maggi, D | 1 |
| Guglielmi, C | 1 |
| Pantano, AL | 1 |
| Defeudis, G | 1 |
| Fioriti, E | 1 |
| Manfrini, S | 1 |
| Pozzilli, P | 1 |
| Giarrusso, R | 1 |
| Lo Monaco, I | 1 |
| Muraca, U | 1 |
| Ricchieri, F | 1 |
| Campedelli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Myoinositol Supplementation, Insulin Resistance and Fetal Sonographic Parameters in Gestational Diabetes, Diet Treated: a Prospective, Randomized, Placebo-controlled Study[NCT03763669] | 120 participants (Actual) | Interventional | 2018-11-14 | Completed | |||
| A Pilot Study of D-Chiro-Inositol Plus Folic Acid in Overweight Patients With Type 1 Diabetes[NCT02730949] | Phase 3 | 26 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for inositol and Overweight
| Article | Year |
|---|---|
The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis.
Topics: Diabetes, Gestational; Dietary Supplements; Female; Humans; Hypertension, Pregnancy-Induced; Infant, | 2023 |
Prevention of gestational diabetes mellitus: Where are we now?
Topics: Diabetes, Gestational; Diet; Dietary Supplements; Exercise Therapy; Female; Humans; Hypoglycemic Age | 2015 |
Inositol as putative integrative treatment for PCOS.
Topics: Female; Humans; Hyperandrogenism; Hyperinsulinism; Inositol; Inositol Phosphates; Insulin; Insulin R | 2016 |
10 trials available for inositol and Overweight
| Article | Year |
|---|---|
The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial.
Topics: Diabetes, Gestational; Dietary Supplements; Female; Folic Acid; Humans; Inositol; Insulin Resistance | 2023 |
Time-to-conception and clinical pregnancy rate with a myo-inositol, probiotics, and micronutrient supplement: secondary outcomes of the NiPPeR randomized trial.
Topics: Dietary Supplements; Double-Blind Method; Female; Humans; Inositol; Micronutrients; Obesity; Overwei | 2023 |
Myo-inositol supplementation to prevent gestational diabetes in overweight non-obese women: bioelectrical impedance analysis, metabolic aspects, obstetric and neonatal outcomes - a randomized and open-label, placebo-controlled clinical trial.
Topics: Diabetes, Gestational; Dietary Supplements; Electric Impedance; Female; Folic Acid; Humans; Infant, | 2021 |
A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients.
Topics: Adolescent; Adult; Female; Humans; Inositol; Italy; Lactalbumin; Mexico; Overweight; Polycystic Ovar | 2021 |
Effects of a Carob-Pod-Derived Sweetener on Glucose Metabolism.
Topics: Adolescent; Adult; Aged; Animals; Beverages; Blood Glucose; Body Mass Index; Complement C4a; Diabete | 2018 |
Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
Topics: Adult; Body Mass Index; Dietary Supplements; Family Health; Female; Gonadotropin-Releasing Hormone; | 2014 |
Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial.
Topics: Adult; Blood Glucose; Body Mass Index; Diabetes, Gestational; Dietary Supplements; Female; Humans; I | 2016 |
A pilot study of D-chiro-inositol plus folic acid in overweight patients with type 1 diabetes.
Topics: Adolescent; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Female; Folic Acid; Humans; Inositol; I | 2017 |
[Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
Topics: Adolescent; Adult; Body Composition; Combined Modality Therapy; Drug Therapy, Combination; Female; H | 2012 |
Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Topics: Adult; Body Mass Index; Dietary Supplements; Female; Folic Acid; Follicle Stimulating Hormone; Gluco | 2012 |
6 other studies available for inositol and Overweight
| Article | Year |
|---|---|
Effect of d-chiro-inositol and alpha-lipoic acid combination on COH outcomes in overweight/obese PCOS women.
Topics: Adult; Drug Therapy, Combination; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotr | 2020 |
Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder.
Topics: Adolescent; Adult; Aspartic Acid; Bipolar Disorder; Body Mass Index; Brain; Case-Control Studies; Cr | 2017 |
Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetes, Gestational; Dietary Supplements; Female; Fetal Growth R | 2018 |
Effects of three treatment modalities (diet, myoinositol or myoinositol associated with D-chiro-inositol) on clinical and body composition outcomes in women with polycystic ovary syndrome.
Topics: Adult; Body Composition; Diet Therapy; Female; Folic Acid; Humans; Inositol; Inositol Phosphates; Me | 2019 |
Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
Topics: Adult; Androstenedione; Drug Therapy, Combination; Estradiol; Female; Follicle Stimulating Hormone; | 2019 |
Alterations in thyroid function among the different polycystic ovary syndrome phenotypes.
Topics: Adult; Body Mass Index; Drug Therapy, Combination; Female; Hospitals, University; Humans; Hypoglycem | 2013 |